Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector

Toro, Haroldo; Tang, De-chu C.; Suarez, David L.; Sylte, Matthew J.; Pfeiffer, Jennifer; Kampen, Kent R. Van

doi:10.1016/j.vaccine.2006.09.047

Cited by 81 publications

(60 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunization and highly pathogenic H5N1 challenge study. In ovo vaccination of 18-day-old embryonated specific-pathogen-free chicken eggs was performed as described previously (45). Briefly, the eggs were candled, and a small hole was made through the air cell with a drill.…”

Section: Vol 81 2007mentioning

confidence: 99%

A New Generation of Modified Live-Attenuated Avian Influenza Viruses Using a Two-Strategy Combination as Potential Vaccine Candidates

Song

Ramírez-Nieto

Pérez

2007

J Virol

123

View full text Add to dashboard Cite

In light of the recurrent outbreaks of low pathogenic avian influenza (LPAI) and highly pathogenic avian influenza (HPAI), there is a pressing need for the development of vaccines that allow rapid mass vaccination. In this study, we introduced by reverse genetics temperature-sensitive mutations in the PB1 and PB2 genes of an avian influenza virus, A/Guinea Fowl/Hong Kong/WF10/99 (H9N2) (WF10). Further genetic modifications were introduced into the PB1 gene to enhance the attenuated (att) phenotype of the virus in vivo. Using the att WF10 as a backbone, we substituted neuraminidase (NA) for hemagglutinin (HA) for vaccine purposes. In chickens, a vaccination scheme consisting of a single dose of an att H7N2 vaccine virus at 2 weeks of age and subsequent challenge with the wild-type H7N2 LPAI virus resulted in complete protection. We further extended our vaccination strategy against the HPAI H5N1. In this case, we reconstituted an att H5N1 vaccine virus, whose HA and NA genes were derived from an Asian H5N1 virus. A single-dose immunization in ovo with the att H5N1 vaccine virus in 18-day-old chicken embryos resulted in more than 60% protection for 4-week-old chickens and 100% protection for 9-to 12-week-old chickens. Boosting at 2 weeks posthatching provided 100% protection against challenge with the HPAI H5N1 virus for chickens as young as 4 weeks old, with undetectable virus shedding postchallenge. Our results highlight the potential of live att avian influenza vaccines for mass vaccination in poultry.

show abstract

Section: Vol 81 2007mentioning

confidence: 99%

A New Generation of Modified Live-Attenuated Avian Influenza Viruses Using a Two-Strategy Combination as Potential Vaccine Candidates

Song

Ramírez-Nieto

Pérez

2007

J Virol

123

View full text Add to dashboard Cite

show abstract

“…However, the intense stress caused by injection could hamper the animal's growth (34). Thus, many investigators are pursuing more convenient and economical avenues for construction of new vaccine candidates, such as recombinant subunit vaccines using baculovirus (28), plasmid DNA (3), or replication-incompetent adenovirus (rAd) (26,27) vectors. The H5N1 strain can infect animals through their respiratory and intestinal tracts (10).…”

mentioning

confidence: 99%

Mucosal and Systemic Immune Responses Induced by Recombinant Lactobacillus spp. Expressing the Hemagglutinin of the Avian Influenza Virus H5N1

Wang

Gao

et al. 2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

To develop a safe, effective, and convenient vaccine for the prevention of highly pathogenic avian influenza (HPAI), we have successfully constructed two recombinant lactobacillus strains (LA4356-pH and DLD17-pH) that express the foreign HPAI virus protein hemagglutinin 1 (HA 1 ). The mucosal and systemic immune responses triggered by these two recombinant lactobacilli following oral administration to BALB/c mice were evaluated. The results showed that both LA4356-pH and DLD17-pH could significantly increase the specific anti-HA 1 IgA antibody level in the mucosa and the anti-HA 1 IgG level in serum, as well as stimulating the splenic lymphocyte proliferative reaction through increased expression of interleukin-4 (IL-4). Compared with LA4356-pH, DLD17-pH was more effective at inducing systemic and mucosal immune responses, with higher anti-HA 1 -specific IgA and IgG levels. Therefore, DLD17-pH could be a promising oral vaccine candidate against HPAI. Highly pathogenic avian influenza (HPAI) virus (H5N1) is a threat to the world's poultry industry. As a zoonotic agent, this virus also has the potential to cause a human pandemic (29). Current vaccination (by intramuscular immunization) against HPAI has succeeded in reducing morbidity and mortality in poultry. However, the intense stress caused by injection could hamper the animal's growth (34). Thus, many investigators are pursuing more convenient and economical avenues for construction of new vaccine candidates, such as recombinant subunit vaccines using baculovirus (28), plasmid DNA (3), or replication-incompetent adenovirus (rAd) (26, 27) vectors. The H5N1 strain can infect animals through their respiratory and intestinal tracts (10). Because there are many mucosa-associated lymphoid tissues underneath the epithelia of the respiratory and intestinal tracts, protective HPAI virus antigens may induce an effective mucosal immune response to prevent the invasion of HPAI virus if they can be transported easily to these tissues. Thus, developing mucosal vaccine candidates based on these considerations is a feasible strategy.Mucosal vaccines, which are administered mainly orally or intranasally, cause less stress in the animal and have been the subject of growing interest due to the advantages that they offer over conventional parenteral vaccines. The biggest advantage is the stimulation of mucosal immune responses (15,24). Lactobacillus is a genus of Gram-positive facultative anaerobic or microaerophilic rod-shaped bacteria. These beneficial bacteria normally live in the digestive, urinary, and genital systems without causing disease. Their abilities to transit through the stomach intact and to associate closely with the intestinal epithelium, combined with their immunomodulatory properties, have made Lactobacillus spp. attractive candidates as live vehicles for the delivery of immunogens to the intestinal mucosa (6, 12). It was recently shown that specific Lactobacillus species can induce inflammatory responses against infection, increase IgA production, activate mo...

show abstract

“…In breeders and layers, it would be more acceptable, since vaccine traces are not expected to be detected in eggs and offspring. Toro et al described an interesting vaccination technology that proposed the use of robotic injectors for in ovo immunization of an adenovirus-based vaccine encoding the H5N9-derived hemag- (28,29). Therefore, we also tested the in ovo immunization route for comparison.…”

Section: Discussionmentioning

confidence: 99%

“…Recent reports indicated that the in ovo route of administration can be effective, with the potential to provide an easy and rapid way to immunize a large number of eggs with an adenovirus-based vaccine via robotic in ovo injectors (1,29). Different doses of Ad5.HA (10 7 to 10 10 ) or Ad5 (control) vaccine were injected into the allantoic cavity of 18-day-old embryonated chicken eggs.…”

Section: Route Of Administration Of the Ad5ha Vaccine In Chickensmentioning

confidence: 99%

Assessment of Route of Administration and Dose Escalation for an Adenovirus-Based Influenza A Virus (H5N1) Vaccine in Chickens

Steitz

Wagner

Bristol

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Highly pathogenic avian influenza (HPAI) virus causes one of the most economically devastating poultry diseases. An HPAI vaccine to prevent the disease in commercial and backyard birds must be effective, safe, and inexpensive. Recently, we demonstrated the efficacy of an adenovirus-based H5N1 HPAI vaccine (Ad5.HA) in chickens. To further evaluate the potential of the Ad5.HA vaccine and its cost-effectiveness, studies to determine the minimal effective dose and optimal route of administration in chickens were performed. A dose as low as 10 7 viral particles (vp) of adenovirus-based H5N1 vaccine per chicken was sufficient to generate a robust humoral immune response, which correlated with the previously reported level of protection. Several routes of administration, including intratracheal, conjunctival, subcutaneous, and in ovo routes, were evaluated for optimal vaccine administration. However, only the subcutaneous route of immunization induced a satisfactory level of influenza virus-specific antibodies. Importantly, these studies established that the vaccine-induced immunity was cross-reactive against an H5N1 strain from a different clade, emphasizing the potential of cross-protection. Our results suggest that the Ad5.HA HPAI vaccine is safe and effective, with the potential of cross-clade protection. The ease of manufacturing and cost-effectiveness make Ad5.HA an excellent avian influenza vaccine candidate with the ability to protect poultry from HPAI virus infection. Considering the limitations of the influenza vaccine technology currently used for poultry applications, any effort aimed at overcoming those limitations is highly significant.

show abstract

Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector

Cited by 81 publications

References 25 publications

A New Generation of Modified Live-Attenuated Avian Influenza Viruses Using a Two-Strategy Combination as Potential Vaccine Candidates

A New Generation of Modified Live-Attenuated Avian Influenza Viruses Using a Two-Strategy Combination as Potential Vaccine Candidates

Mucosal and Systemic Immune Responses Induced by Recombinant Lactobacillus spp. Expressing the Hemagglutinin of the Avian Influenza Virus H5N1

Assessment of Route of Administration and Dose Escalation for an Adenovirus-Based Influenza A Virus (H5N1) Vaccine in Chickens

Contact Info

Product

Resources

About